CoChat

PET/CT in diagnosis of dementia

Open access
Berti, Valentina, Pupi, Alberto, Mosconi, Lisa · 2011 · Annals of the New York Academy of Sciences
Cited by 95

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Clinical use of positron emission tomography (PET) is now well established in neurodegenerative disorders, especially in the diagnosis of dementia. Measurement of cerebral glucose metabolism is of significant value, and it facilitates early diagnosis, appropriate differential diagnosis, and the evaluation of drug treatment in patients with dementia. In addition, tracers offer new perspectives for studying the neuropathology of underlying dementia, such as the accumulation of amyloid proteins, tau‐proteins, or the presence of neuroinflammation. Finally, PET tracer studies of different neurotransmitter systems in dementia may not only increase the understanding of pathophysiologic mechanisms of the different disorders, but also improve diagnostic accuracy. In conclusion, PET imaging with different tracers offers reliable biomarkers in dementia, which can assist clinicians in the diagnosis of different dementing disorders, especially in the situation of overlapping phenotypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1749-6632.2011.06015.x

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

  • PET/MRI: Where might it replace PET/CT?

    Ehman, E. C., Johnson, G. B., Villanueva‐Meyer, J. E., Cha, S., Leynes, A. P., Larson, P. E. Z., & Hope, T. A. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25711 · Cited by 271

  • Noninvasive Molecular Imaging of Neuroinflammation

    Jacobs, A. H., Tavitian, B., & the INMiND consortium (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.53 · Cited by 245

    “In an elegant imaging-guided study by Keller et al, it was shown in the glial fibrillary acidic protein-luc/SOD1G93A reporter mouse model of ALS that interfering with microglia activity by means of minocycline at various disease stages either ameliorates (at early stages) or enhances (at later stages) disease activity…”
    BackgroundInfluential
  • Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease

    Mhatre, S. D., Tsai, C. A., Rubin, A. J., James, M. L., & Andreasson, K. I. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.006 · Cited by 134

    “In addition, PET is being used to monitor the effects of novel AD therapeutics in clinical trials, and is providing a non-invasive picture of the molecular underpinnings of this complex neurodegenerative disease in a longitudinal manner [126].”
  • The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer’s Disease

    Ogunmokun, G., Dewanjee, S., Chakraborty, P., Valupadas, C., Chaudhary, A., Kolli, V., Anand, U., Vallamkondu, J., Goel, P., Paluru, H. P. R., et al. (2021) · Cells · doi:10.3390/cells10102790 · Cited by 85

    “Brain hypometabolism map PET scan analysis corroborated that the activation of microglial regional clusters in the brains of individuals is predominantly involved in the transition from healthy status to dementia [23], which divulges the involvement of inflammation in neurodegeneration leading to AD.”
    Background

See all 95

Metadata

Authors
Berti, V., Pupi, A., & Mosconi, L.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2011-06
Volume
1228
Issue
1
Pages
81-92
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W1674464860
Cited by
95
References
26
FWCI
4.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.